NervGen Completes $23 Million Bought Deal Financing

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

NervGen Engages Russo Partners LLC to Provide Public Relations Services
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Canadian Investment Regulatory Organization Trade Resumption - NGEN
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
Canadian Investment Regulatory Organization Trading Halt - NGEN
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
NervGen Pharma Grants Stock Options
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.